Adipose Tissue Dysfunction Increases Fatty Liver Association with Pre Diabetes and Newly Diagnosed Type 2 Diabetes Mellitus

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2016 Nov 16

PMID 27843495

Citations 8

Authors

Esteban Jorge-Galarza

Aida Medina-Urrutia

Rosalinda Posadas-Sanchez

Carlos Posadas-Romero

Guillermo Cardoso-Saldana

Gilberto Vargas-Alarcon

Nacu Caracas-Portilla

Carmen Gonzalez-Salazar

Margarita Torres-Tamayo

Juan Gabriel Juarez-Rojas

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the role of adipose tissue function on the association of fatty liver (FL) with impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes mellitus (nT2D).

Methods: In 1264 subjects, computed tomography was used to evaluate FL and elevated visceral adipose tissue (VAT). Fasting plasma glucose, <5.6, 5.6-6.9 and ≥7 mmol/l, were used to defined normoglycemic (NG), IFG or nT2D, respectively. Elevated free fatty acids, low serum adiponectin levels and adipose tissue insulin resistance (Adipo-IR), were used as markers of adipose tissue dysfunction.

Results: Compared to NG subjects, those with IFG or nT2D had higher prevalence of FL and elevated VAT. FL was found to be independently associated with IFG and nT2D. Adipo-IR increased the association between FL and IFG [OR: 2.46 (95% I.C.: 1.73-3.49) to 5.42 (3.11-9.41)], whereas low adiponectin levels had a higher effect on the FL and nT2D association [OR: 4.26 (2.18-8.34) to 8.53 (2.96-24.55)].

Conclusion: Fatty liver was independently associated with IFG and nT2D. Our results indicate for the first time, that adipose tissue dysfunction increases these associations.

Citing Articles

Triglyceride-glucose index is associated with the risk of impaired fasting glucose in Chinese elderly individuals.

Liu J, Yi F, Duan K, Liu H Sci Rep. 2024; 14(1):16033.

PMID: 38992112 PMC: 11239658. DOI: 10.1038/s41598-024-67081-y.

Label-free optical metabolic imaging of adipose tissues for prediabetes diagnosis.

Chen L, Qin G, Liu Y, Li M, Li Y, Guo L Theranostics. 2023; 13(11):3550-3567.

PMID: 37441598 PMC: 10334843. DOI: 10.7150/thno.82697.

Adipose tissue dysfunction serum markers are associated with high density lipoprotein size and glycation in the early stages of type 2 diabetes.

Jorge-Galarza E, Medina-Urrutia A, Reyes-Barrera J, Torres-Tamayo M, Montano-Estrada L, Paez-Arenas A Lipids Health Dis. 2023; 22(1):89.

PMID: 37391843 PMC: 10314544. DOI: 10.1186/s12944-023-01847-7.

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.

Volpe S, Lisco G, Racaniello D, Fanelli M, Colaianni V, Vozza A Nutrients. 2022; 14(12).

PMID: 35745144 PMC: 9227575. DOI: 10.3390/nu14122414.

Cardiovascular autonomic responses during head-up tilt test in newly diagnosed type 2 diabetes.

Jorge-Galarza E, Torres-Tamayo M, Martinez-Alvarado M, Pena-Aparicio B, Gonzalez-Salazar C, Reyes-Barrera J Ir J Med Sci. 2021; 191(5):2077-2084.

PMID: 34750734 DOI: 10.1007/s11845-021-02825-7.

References

Ginsberg H, Zhang Y, Hernandez-Ono A . Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring). 2006; 14 Suppl 1:41S-49S. DOI: 10.1038/oby.2006.281. View

Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28(1):88-136. DOI: 10.1093/eurheartj/ehl260. View

McKimmie R, Daniel K, Carr J, Bowden D, Freedman B, Register T . Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol. 2008; 103(12):3029-35. PMC: 3638961. DOI: 10.1111/j.1572-0241.2008.02188.x. View

Guilherme A, Virbasius J, Puri V, Czech M . Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9(5):367-77. PMC: 2886982. DOI: 10.1038/nrm2391. View

Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov V . Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012; 35(4):873-8. PMC: 3308295. DOI: 10.2337/dc11-1849. View

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

Despres J . Is visceral obesity the cause of the metabolic syndrome?. Ann Med. 2006; 38(1):52-63. DOI: 10.1080/07853890500383895. View

Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C . Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2011; 55(5):1389-97. DOI: 10.1002/hep.25539. View

Navarro-Gonzalez J, Mora-Fernandez C . The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008; 19(3):433-42. DOI: 10.1681/ASN.2007091048. View

10.

Kishida K, Funahashi T, Shimomura I . Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014; 28(1):119-30. DOI: 10.1016/j.beem.2013.08.006. View

11.

Hajer G, van Haeften T, Visseren F . Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008; 29(24):2959-71. DOI: 10.1093/eurheartj/ehn387. View

12.

Kelley D, McKolanis T, Hegazi R, Kuller L, Kalhan S . Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003; 285(4):E906-16. DOI: 10.1152/ajpendo.00117.2003. View

13.

. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2015; 39 Suppl 1:S13-22. DOI: 10.2337/dc16-S005. View

14.

Armstrong M, Hazlehurst J, Hull D, Guo K, Borrows S, Yu J . Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014; 16(7):651-60. PMC: 4190688. DOI: 10.1111/dom.12272. View

15.

Fabbrini E, Sullivan S, Klein S . Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2009; 51(2):679-89. PMC: 3575093. DOI: 10.1002/hep.23280. View

16.

Ye J . Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond). 2008; 33(1):54-66. PMC: 2650750. DOI: 10.1038/ijo.2008.229. View

17.

Balkau B, Lange C, Vol S, Fumeron F, Bonnet F . Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010; 10:56. PMC: 2898845. DOI: 10.1186/1471-230X-10-56. View

18.

Limanond P, Raman S, Lassman C, Sayre J, Ghobrial R, Busuttil R . Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2003; 230(1):276-80. DOI: 10.1148/radiol.2301021176. View

19.

Retnakaran R, Ye C, Hanley A, Harris S, Zinman B . Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Obes Metab. 2011; 14(1):91-3. DOI: 10.1111/j.1463-1326.2011.01481.x. View

20.

Cheng S, Wiklund P, Autio R, Borra R, Ojanen X, Xu L . Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015; 10(10):e0138889. PMC: 4595021. DOI: 10.1371/journal.pone.0138889. View